Company Filing History:
2 out of 2 
1 out of 1 
1 out of 21 Years Active: 2020-2025
Title: The Innovative Contributions of Helen Toni Jun
Introduction
Helen Toni Jun, based in San Diego, CA, is a prominent inventor with two registered patents. Her work in the field of immunology has opened new avenues for therapeutic and diagnostic applications, particularly concerning various diseases and disorders.
Latest Patents
One of Helen’s latest inventions focuses on Anti-interleukin-11 receptor subunit α (IL-11Rα) antibodies. This patent describes antibodies and their binding fragments that specifically target the human interleukin-11 receptor subunit α (IL-11Rα). These antibodies have the potential to be utilized in a wide range of therapeutic and diagnostic methods, particularly in the treatment and diagnosis of cancers, inflammatory diseases, autoimmune diseases, and more.
Another significant patent involves antibodies directed against lymphocyte activation gene 3 (LAG-3). This invention encompasses an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that specifically bind to a protein encoded by the LAG-3 gene. The LAG-3-binding agent created from these polypeptides can be employed to treat disorders sensitive to LAG-3 inhibition, such as various cancers and infectious diseases.
Career Highlights
Helen has made notable contributions during her career, having worked with companies such as Anaptysbio, Inc. and Lassen Therapeutics, Inc. Her experience in these organizations has allowed her to develop and refine her innovative ideas into practical applications that benefit healthcare.
Collaborations
Throughout her career, Helen has collaborated with respected professionals in her field, including David J King and Marilyn Kehry. These collaborations have likely enriched her research and contributed to her successes as an inventor.
Conclusion
Helen Toni Jun stands out as an influential inventor whose work in immunology continues to impact the medical field significantly. With her innovative patents and professional collaborations, she demonstrates the potential of targeted therapies in addressing serious health challenges.